Virpax Pharmaceuticals, Inc. has reported significant changes in its corporate structure and accounting practices. On September 20, 2024, the company's independent registered public accounting firm, EisnerAmper LLP, resigned. The audit reports for the fiscal years ending December 31, 2023, and December 31, 2022, by EisnerAmper did not contain any adverse opinions but included a paragraph about the company's ability to continue as a going concern. There were no disagreements on accounting principles or practices during the two fiscal years. Following the resignation, Virpax Pharmaceuticals appointed a new auditor, Bush & Associated CPA LLC, on September 24, 2024, as approved by the Audit Committee and ratified by the Board of Directors. Additionally, on the same day as the auditor's resignation, Eric Floyd, Chairman of the Board, resigned from his position and all committee roles due to disagreements with the Board's policies and practices, including salary reductions and the elimination of directors' and officers' insurance. These changes come at a critical time for the company and are disclosed in the company's recent SEC filings.

Virpax Pharmaceuticals, Inc. has reported significant changes in its corporate structure and accounting practices. On September 20, 2024, the company's independent registered public accounting firm, EisnerAmper LLP, resigned. The audit reports for the fiscal years ending December 31, 2023, and December 31, 2022, by EisnerAmper did not contain any adverse opinions but included a paragraph about the company's ability to continue as a going concern. There were no disagreements on accounting principles or practices during the two fiscal years. Following the resignation, Virpax Pharmaceuticals appointed a new auditor, Bush & Associated CPA LLC, on September 24, 2024, as approved by the Audit Committee and ratified by the Board of Directors. Additionally, on the same day as the auditor's resignation, Eric Floyd, Chairman of the Board, resigned from his position and all committee roles due to disagreements with the Board's policies and practices, including salary reductions and the elimination of directors' and officers' insurance. These changes come at a critical time for the company and are disclosed in the company's recent SEC filings.